WEREWOLF THERAPEUTICS, INC. Restricted Cash and Cash Equivalents
WEREWOLF THERAPEUTICS, INC. (HOWL) had Restricted Cash and Cash Equivalents of $900.00 thousand as of 2025-12-31, per its S-4 filed 2026-09-22.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-09-22
- 2025-12-31: Restricted Cash and Cash Equivalents $900.00K.
- 2024-12-31: Restricted Cash and Cash Equivalents $1.20M.
- 2023-12-31: Restricted Cash and Cash Equivalents $21.20M.
- 2023-09-30: Restricted Cash and Cash Equivalents $21.20M.
| Period end | Restricted Cash and Cash Equivalents | Restricted Cash and Cash Equivalents as first filed |
|---|---|---|
| 2025-12-31 | $900.00K S-4 · filed 2026-09-22 | |
| 2024-12-31 | $1.20M S-4 · filed 2026-09-22 | |
| 2023-12-31 | $21.20M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $21.20M 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $1.20M 10-K · filed 2024-03-07 | $1.21M 10-K · filed 2023-03-23 |
| 2021-12-31 | $1.30M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $207.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |